Trials / Unknown
UnknownNCT03734926
A Phase 1 Study of ZSP1241 in Participants With Advanced Solid Tumors
A Phase 1, Open-Label, Dose-Escalation and Expansion, Safety and Tolerability Study of ZSP1241 in Participants With Advanced Solid Tumors
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 90 (estimated)
- Sponsor
- Guangdong Zhongsheng Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics, and determine the maximum tolerated dose of ZSP1241 in participants with hepatocellular carcinoma, cholangiocarcinoma, gastric cancer, esophageal cancer, colorectal cancer and other advanced solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ZSP1241 | ZSP1241 tablets for oral administration. |
Timeline
- Start date
- 2018-11-13
- Primary completion
- 2021-10-31
- Completion
- 2021-10-31
- First posted
- 2018-11-08
- Last updated
- 2020-07-22
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03734926. Inclusion in this directory is not an endorsement.